Symrise AG has finalized the sale of its terpene business, AmeriTerpenes LLC, to Mutares SE & Co. KGaA, marking a significant strategic move for both companies.
In a strategic move to optimize its portfolio, Symrise AG has completed the sale of its terpene ingredients businessAmeriTerpenes LLC to Mutares SE & Co. KGaA. This transaction aligns with Symrise’s ONE Symrise strategy focusing on core growth platforms while ensuring continuity for customers and suppliers.
The divestment positions AmeriTerpenes under Mutares’ ownership for long-term growth, particularly in the renewable terpenes market for fragrance, flavor, and industrial applications. AmeriTerpenes operates production facilities in Jacksonville, Florida and Colonels Island, Georgia supplying key ingredients to global manufacturers.
Strategic alignment with Symrise’s growth objectives
The sale enables Symrise to sharpen its portfolio focus, directing resources toward its central growth platforms. Dr. Jean-Yves Parisot CEO of Symrise, emphasized the transaction’s role in positioning the company for future success: “This deal demonstrates our commitment to active portfolio management and strategic growth.”
AmeriTerpenes, a leader in renewable terpene ingredients, will benefit from Mutares’ expertise in corporate carve-outs and operational excellence.
The transaction ensures continued supply agreements, securing Symrise’s access to terpene-based raw materials and maintaining strong industry partnerships.
Mutares expands chemical portfolio and US presence
For Mutares, the acquisition strengthens its Chemicals & Materials segment and expands its footprint in the US market. Johannes Laumann CIO of Mutares, highlighted the strategic fit: “AmeriTerpenes aligns perfectly with our investment approach, targeting businesses with significant improvement potential.”
The transaction supports Mutares’ growth strategy in the chemicals sector and reinforces its presence in North America. Both companies are committed to a smooth transition, ensuring uninterrupted service for customers and suppliers.
Financial implications and future outlook
Symrise expects a non-cash impairment charge in the mid-tens of millions of euros, impacting its 2026 financial results. Despite this, the divestment supports Symrise’s long-term goal of sustainable profitability and operational excellence.
Looking ahead, Symrise and AmeriTerpenes will continue their long-standing business relationship under the new ownership structure. The transaction underscores both companies’ commitment to innovation and strategic growth in the specialty chemicals sector.
